The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Laboratory values meet the criteria specified in the protocol.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion Criteria:
* History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
* Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
* Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
* Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.
Primary outcome measure(s)
Maximum Observed Plasma Concentration (Cmax) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 Cmax of ABBV-722
Time to Cmax (Tmax) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 Tmax of ABBV-722
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 AUCt of ABBV-722
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 AUCinf of ABBV-722
Terminal Phase Elimination Rate Constant (β) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 β of ABBV-722
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722 — Up to Day 8 in Period 1 and Up to Day 14 in Period 2 t1/2 of ABBV-722
Number of Participants with Adverse Events (AEs) — Up to Approximately 45 Days An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.